Thyrocare Technologies (Small Cap) Share Target 2025, 2026 To 2035
|
Thyrocare Technologies Limited |
|||
|
Price: ₹725.85 (+1.43%) | ||
| 52 Week Low: ₹554.10 52 Week High: ₹1,055.00 |
|||
| Market Capital: 3,332.02 Crore (Smallcap) | |||
| Healthcare -> Diagnostics & Research | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Thyrocare Technologies Share Price Target For 2025
- 1.1.1: Thyrocare Technologies Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Thyrocare Technologies Share Price Target For 2026
- 1.2.1: Thyrocare Technologies Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Thyrocare Technologies Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Thyrocare Technologies Brief Company Overview
- 4: Thyrocare Technologies Financial Performance
- 4.0.1: Is Thyrocare Technologies A Good Buy For Long Term?
Thyrocare Technologies, a Small Cap company in the Diagnostics & Research Industry has delivered 23.8% returns in 5-year showing 13.5% quarterly revenue growth with 12.4% profit margin.
To predict the Thyrocare Technologies's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Thyrocare Technologies Share Price Target For 2025
The line chart displays the monthly closing prices of Thyrocare Technologies with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Thyrocare Technologies shares in 2025, see the table below.
Thyrocare Technologies Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 818.1 (+12.7%) | Price Action: 09 Oct 2024 Low |
| 2025 Target 2 | 810.0 (+11.59%) | Price Action: 27 Sep 2024 Low |
| 2025 Target 1 | 800.4 (+10.27%) | Price Action: 09 Aug 2024 Low |
| Current Price | 725.85 | Thyrocare Technologies's share price as of 25 Feb 2025 |
| Stop Loss 1 | 690.35 (-4.9%) | Price Action: Feb 2017 Low |
| Stop Loss 2 | 682.25 (-6.01%) | Price Action: 06 Mar 2024 High |
| Stop Loss 3 | 675.0 (-7.01%) | Price Action: 21 Dec 2023 High |
Short-Term Technical Outlook
Current Technical Position: Thyrocare Technologies is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹761.28 serves as the nearest technical reference point.
Historical Returns: 3-month: -27.44% | 6-month: -14.02% | 1-year: +7.32%
Thyrocare Technologies Share Price Target For 2026
The line chart displays the monthly closing prices of Thyrocare Technologies with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Thyrocare Technologies shares in 2026, see the table below.
Thyrocare Technologies Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1162.66 (+60.17%) | Price Action: Chart |
| 2026 Target 2 | 1140.98 (+57.19%) | Price Action: Chart |
| 2026 Target 1 | 1129.68 (+55.63%) | Fibonacci Extension Level 64.90% |
| Current Price | 725.85 | Thyrocare Technologies's share price as of 25 Feb 2025 |
| Stop Loss 1 | 633.0 (-12.8%) | Price Action: 08 Dec 2023 High |
| Stop Loss 2 | 626.55 (-13.69%) | Price Action: 12 Dec 2023 High |
| Stop Loss 3 | 620.0 (-14.59%) | Price Action: Jun 2018 High |
Long-Term Technical Outlook
52-Week Range Analysis: Thyrocare Technologies is currently trading at 34.3% of its 52-week range (₹554.1 - ₹1055).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +7.32% | 3-year: -15.41% | 5-year: +23.77%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Thyrocare Technologies Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹725.85 | ||
| 2025 | ₹1,090.45 | +50.23% | ₹1,106.81 |
| 2026 | ₹1,239.50 | +13.66% | ₹1,258.09 |
| 2027 | ₹1,467.89 | +18.42% | ₹1,489.91 |
| 2028 | ₹1,769.45 | +20.54% | ₹1,795.99 |
| 2029 | ₹1,950.06 | +10.2% | ₹1,979.31 |
| 2030 | ₹2,246.06 | +15.17% | ₹2,279.75 |
| 2031 | ₹2,839.99 | +26.44% | ₹2,882.59 |
| 2032 | ₹3,047.07 | +7.29% | ₹3,092.78 |
| 2033 | ₹3,607.61 | +18.39% | ₹3,661.72 |
| 2034 | ₹3,935.56 | +9.09% | ₹3,994.59 |
| 2035 | ₹4,408.95 | +12.02% | ₹4,475.08 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Thyrocare Technologies Brief Company Overview
Thyrocare Technologies Limited: Unraveling the Diagnostics Giant Founded in 1996, Thyrocare Technologies Limited has emerged as a prominent player in India's diagnostic services industry, catering to patients, laboratories, and hospitals. They offer a comprehensive range of...
medical diagnostic tests, focusing on early detection and management of various disorders. Their renowned Aarogyam brand provides patients with a suite of wellness and preventive healthcare tests. The company's commitment to providing affordable and accessible diagnostics has earned it a strong reputation in the industry. Thyrocare's advanced technology and expertise enable them to deliver accurate and timely results, empowering patients to make informed healthcare decisions. Thyrocare's diverse product portfolio includes glucometers, glucostrips, consumables, and radiopharmaceuticals, catering to a wide range of diagnostic needs.Thyrocare Technologies Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 3,332.02 Crore | Market valuation of Thyrocare Technologies's shares. |
| Revenue (TTM) | 571.87 Crore | Total revenue generated by Thyrocare Technologies over the past twelve months. |
| Net Income (TTM) | +70.76 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +13.45% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +12.37% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+13.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+42.6% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
8.02 | Company's total debt divided by total shareholder equity. |
| Total Debt | 42.34 Crore | Sum of Thyrocare Technologies's current & long-term financial obligations. |
| Total Cash | 179.96 Crore | Total amount of liquid funds available to Thyrocare Technologies. |
| Beta | 0.52 | Beta is less than 1 indicating that the Thyrocare Technologies's price is less volatile than the market. |
Is Thyrocare Technologies A Good Buy For Long Term?
Based on the given data, Thyrocare Technologies is a good buy for long-term investors. The company has shown consistent revenue and earnings growth, with a healthy profit margin. It has also reduced debt and increased cash balance in the recent quarter. While the company's returns have been volatile in the short term, it has delivered strong returns over the past 12 months and 5 years.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
